Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies, Journal of Hematology & Oncology

Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Case Study - COVALfinder to Study Irreversible EGFR Drugs

Haematologica, Volume 108, Issue 1 by Haematologica - Issuu

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib

Frontiers Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies, Journal of Hematology & Oncology

Full article: Drug delivery targets and strategies to address mast cell diseases

Proteomics and Beyond: Cell Decision-Making Shaped by Reactive Electrophiles: Trends in Biochemical Sciences

Deciding between one-step and two-step irreversible inhibition mechanisms on the basis of “kobs” data: A statistical approach

Kinase drug discovery modern approaches 978-1-78801-309-3, 1788013093, 978-1-78801-563-9, 1788015630, 978-1-78801-083-2

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two – topic of research paper in Biological sciences. Download scholarly article PDF and read for

Melissa Hopper - Immunology Doctoral Candidate - Mayo Clinic Graduate School of Biomedical Sciences

PDF) Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations